ReviewBioMed research international2014
Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Review
- Photochemical Targeting of Mitochondria to Overcome Chemoresistance in Ovarian CancerPhotochemistry and photobiology · 2023Review
- Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review).Oncology reports · 2022Review
- Metformin Inducing the Change of Functional and Exhausted Phenotypic Tumor-Infiltrated Lymphocytes and the Correlation with JNK Signal Pathway in Triple-Negative Breast Cancer.Breast cancer (Dove Medical Press) · 2022Article
- Review
- Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells.Cancers · 2020Review
- Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer.Journal of ovarian research · 2020Article
- Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting.Cancers · 2019Review
- HSF1/AMPKα2 mediated alteration of metabolic phenotypes confers increased oxaliplatin resistance in HCC cells.American journal of cancer research · 2019Article
- Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations.Cancer letters · 2018Article
- Article
- Time-Dependent Effects of POT1 Knockdown on Proliferation, Tumorigenicity, and HDACi Response of SK-OV3 Ovarian Cancer Cells.BioMed research international · 2018Article
- Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells.Analytical cellular pathology (Amsterdam) · 2018Article
- Metformin: Possible Use of a Diabetes Drug in Treatment of Cancer.Clinical research in diabetes and endocrinology · 2018Article
- Co-delivery of carboplatin and paclitaxelRSC advances · 2017Article
- 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits.Oncotarget · 2015Article
- Clinical benefits of metformin in gynecologic oncology.Oncology letters · 2015Article
- Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction.Oncotarget · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the most lethal gynecologic malignancy among women worldwide and is presumed to result from the presence of ovarian cancer stem cells. To overcome the limitation of current anticancer agents, another anticancer strategy is necessary to effectively target cancer stem cells in ovarian cancer. In many types of malignancies, including ovarian cancer, metformin, one of the most popular antidiabetic drugs, has been demonstrated to exhibit chemopreventive and anticancer efficacy with respect to incidence and overall survival rates. Thus, the metabolic reprogramming of cancer and cancer stem cells driven by genetic alterations during carcinogenesis and cancer progression could be therapeutically targeted. In this review, the potential efficacy and anticancer mechanisms of metformin against ovarian cancer stem cells will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.